Lupin Receives FDA Approval for New Drug Application for SUPRAX® Oral Suspension, 500 mg/5mL

Mumbai, India And Baltimore (ots/PRNewswire) -

Approval to add to growing SUPRAX(R) Franchise

Pharma major, Lupin Ltd., announced today that its subsidiary,
Lupin Pharmaceuticals Inc. (collectively, Lupin) has received
approval for SUPRAX(R) (Cefixime) for Oral Suspension, 500 mg/5mL
from the United States Food and Drugs Administration (FDA). Lupin
expects to commence shipping the product in the near future.

The approval will expand Lupin's range of SUPRAX(R) dosage forms
available to treat approved indications in appropriate patients.
SUPRAX(R) is currently available as 100 mg/5ml and 200 mg/5ml
suspensions; 400 mg tablets as well as chewable tablets 100 & 200 mg.

This new drug application provides for a new strength, 500mg/5mL,
of SUPRAX (cefixime) for Oral Suspension for the treatment of otitis
media, acute exacerbation of chronic bronchitis, uncomplicated
urinary tract infections, uncomplicated gonorrhea (cervical/urethral)
and pharyngitis/tonsillitis.

Commenting on the approval, Ms. Vinita Gupta, Group President,
Lupin Limited & CEO, Lupin Pharmaceutical Inc. said "We are happy to
receive this approval. The new dosage form will add to our growing
SUPRAX franchise and gives health care providers and patients a new
formulation to treat the indicated infections. The approval of SUPRAX
for Oral Suspension is one more example of our ongoing commitment to
serving our customers and addressing their needs."

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational
pharmaceutical company producing and developing a wide range of
branded and generic formulations and APIs. The Company is a
significant player in the Cardiovascular, Diabetology, Asthma,
Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global
leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in
the US (5.1% market share by prescriptions, IMS Health) and the 3rd
largest Indian pharmaceutical company by sales. The Company is also
the fastest growing top 10 generic pharmaceutical players in Japan
and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated
Total Income and Profit after Tax were Rs. 70,972 million (USD 1.49
billion) and Rs.8,676 million (USD 182 million) respectively. Please
visit http://www.lupinworld.com for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of
Lupin Limited. Headquartered in Baltimore, Maryland, Lupin
Pharmaceuticals, Inc. is dedicated to delivering high-quality,
affordable generic medicines and branded formulations trusted by
healthcare professionals and patients across geographies. For more
information, visit http://www.lupinpharmaceuticals.com.

For further information or queries please contact -

Shamsher Gorawara
Head - Corporate Communications
Lupin Limited
Ph: +91-98-20-338-555
Email: shamshergorawara@lupinpharma.com

ots Originaltext: Lupin Ltd
Im Internet recherchierbar: http://www.presseportal.de